Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab

SL Topalian, FS Hodi, JR Brahmer, SN Gettinger… - JAMA …, 2019 - jamanetwork.com
Importance Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is
approved by the US Food and Drug Administration for treating advanced melanoma, renal …
被引用次数：498 相关文章

Five-Year Survival and Correlates among Patients with Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated with Nivolumab

SL Topalian, FS Hodi, JR Brahmer… - JAMA …, 2019 - scholars.northwestern.edu
Importance: Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is
approved by the US Food and Drug Administration for treating advanced melanoma, renal …
[PDF] researchgate.net

[PDF][PDF] Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

JAMA, 2019 - researchgate.net
OBJECTIVES To analyze long-term overall survival (OS) among patients receiving
nivolumab and identify clinical and laboratory measures associated with tumor regression …

Five-Year Survival and Correlates among Patients with Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated with Nivolumab

SL Topalian, FS Hodi, JR Brahmer… - JAMA …, 2019 - pure.johnshopkins.edu
Importance: Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is
approved by the US Food and Drug Administration for treating advanced melanoma, renal …
[HTML] nih.gov

[HTML][HTML] Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With …

SL Topalian, FS Hodi, JR Brahmer, SN Gettinger… - JAMA …, 2019 - ncbi.nlm.nih.gov
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell
Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab - PMC Back to Top Skip to …

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab

SL Topalian, FS Hodi, JR Brahmer… - JAMA …, 2019 - pubmed.ncbi.nlm.nih.gov
Importance Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is
approved by the US Food and Drug Administration for treating advanced melanoma, renal …

[引用][C] Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

SL Topalian, FS Hodi, JR Brahmer, SN Gettinger… - JAMA Oncology, 2019 - cir.nii.ac.jp
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell
Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab | CiNii Research CiNii …

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

SL Topalian, FS Hodi, JR Brahmer… - JAMA …, 2019 - mpgjournal.mpg.es
Importance Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is
approved by the US Food and Drug Administration for treating advanced melanoma, renal …

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.

SL Topalian, FS Hodi, JR Brahmer, SN Gettinger… - JAMA …, 2019 - europepmc.org
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell
Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. - Abstract - Europe PMC …

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.

SL Topalian, FS Hodi, JR Brahmer, SN Gettinger… - JAMA …, 2019 - europepmc.org
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell
Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. - Abstract - Europe PMC …